Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Clinical trial NCT05336812 · RECRUITING
Trial details
- NCT number
- NCT05336812
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-13
- Primary completion
- 2026-10-31
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.